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Background/purpose: There is a lack of long-term follow-up studies for elderly patients with heart failure
(HF) in primary health care. There is conﬂicting information on prognostic differences between systolic
or diastolic HF in elderly patients. Our aims were, ﬁrst, to study the association between overall HF or
types of HF and all-cause and cardiovascular mortality, and second, to explore the impact of N-terminal
prohormone of brain natriuretic peptide (NTproBNP) and comorbidities.
Methods: A longitudinal, prognostic, observational primary health care study with 10 years of follow-up
comparing an elderly patient population with HF (systolic and/or diastolic HF) to patients without HF
was conducted. HF was diagnosed with echocardiography according to the European Society of Cardi-
ology guidelines.
Results: Seventy-seven of 144 patients (102 women and 42 men; mean age, 77 years) had systolic and/or
diastolic HF and were compared with 67 patients without HF (Reference group). During the 10-year
follow-up, 71 (49%) patients died (women, 68%; men, 32%). In univariate Cox regression analysis, sig-
niﬁcant associations were found for overall HF [hazard ratio (HR), 1.86; 95% conﬁdence interval (CI), 1.15
e3.01], isolated systolic HF (HR, 1.95; 95% CI, 1.06e3.61), and combined (systolic and diastolic) HF (HR,
3.28; 95% CI, 1.74e6.14) with all-cause mortality, but not for isolated diastolic HF. Similar results were
found for cardiovascular mortality. In multivariate analysis, age (HR, 1.11; 95% CI, 1.06e1.17), kidney
dysfunction (HR, 1.91; 95% CI, 1.11e3.29), smoking (HR, 3.70; 95% CI, 2.02e6.77), and NTproBNP (HR, 1.01;
95% CI, 1.00e1.02) signiﬁcantly predicted all-cause mortality, but not any type of HF.
Conclusion: Patients diagnosed with systolic HF had a worse prognosis for mortality compared to the
reference group, but in patients with diastolic HF the prognosis for mortality was similar with that in the
reference group. NTproBNP was a valuable prognostic factor in elderly patients. Emphasis should be
placed on kidney dysfunction and smoking/having smoked.
Copyright © 2014, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.
 
Open access under CC BY-NC-ND license.1. Introduction
In the elderly population (>75 years), the prevalence of heart
failure (HF) is about 10%.1 The prognosis for patients with HF is
poor, comparable to a diagnosis of cancer.2 Severe systolic HF has
the most serious prognosis,3 but whether diastolic HF has the same
ominous prognosis as systolic HF in both younger and elderly pa-
tients is a matter of debate.3e5 Elderly patients, especially females,
are known to more often have diastolic HF than younger patients.6ent of Medicine, Skellefteå
).
linical Gerontology & Geriatrics. PHowever, most HF studies on prognosis are based on younger pa-
tients (<70 years) treated in the hospital,7 but there is limited and
conﬂicting information on prognostic differences between systolic
or diastolic HF in elderly patients. Echocardiography is still the gold
standard for diagnosis of HF, but there is limited use of echocar-
diography in primary health care (PHC) so many of these patients
may be misdiagnosed and misclassiﬁed for prognostic reasons.8 In
PHC, elderly patients often have serious comorbidities, and the
contributions of these comorbidities to the prognosis of patients
with HF are often overlooked.9 N-terminal prohormone of brain
natriuretic peptide (NTproBNP) is a biomarker used to exclude HF,10
but is also frequently used for prognostic purposes.11 Its value in
predicting mortality in elderly patients with systolic and/or dia-
stolic HF requires further evaluation.ublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Table 1
Distribution of echocardiographic variables for systolic and diastolic HF.a
Diagnostic variables Systolic HF (n ¼ 28) Diastolic HF (n ¼ 28)
EF  55% 3 28
EF 30e<55% 23 0
Abnormal E/A 15
Abnormal IVRT 13
Abnormal S/D 5
Normal E/A 13 9
Normal IVRT 8 9
Normal S/D 9 15
E/A¼ ratio of early (E) and atrial (A) ﬁlling; EF¼ ejection fraction; HF¼ heart failure;
IVRT ¼ isovolumic relaxation time; S/D ¼ ratio of systolic (S) and diastolic (D)
components in the pulmonary vein inﬂow.
a Classiﬁcation for diastolic HF is as follows. The E/A ratio was classiﬁed as age-
dependent and considered abnormal when E/A < 1 (40e49 years), E/A < 0.9
(50e59 years), E/A < 0.8 (60e69 years), E/A < 0.7 (70e80 years), and E/A < 0.7
(>80 years).1 The relation between the S and D components of the pulmonary vein
inﬂow was assessed and S/D < 1 was considered abnormal in age > 60 years and S/
D < 0.9 was considered abnormal in age < 60 years. The IVRT value was also clas-
siﬁed by age as follows: IVRT >85 milliseconds (40e49 years),
IVRT > 90 milliseconds (50e59 years), IVRT > 95 milliseconds (60e69 years), and
IVRT > 100milliseconds (>70 years) is abnormal value and <70ms is abnormal in all
ages.13,14
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tients with HF in the PHC setting with regard to all-cause as well as
cardiovascular mortality, and the prognostic impact of comorbid-
ities.12 The comorbidities may inﬂuence the prognosis beyond the
type of HF in the short term; therefore, different follow-up periods
need to be evaluated.
1.1. Aims
The primary objective of this study was to investigate the as-
sociation between overall HF or speciﬁc types of HF and all-cause
and cardiovascular mortality. The secondary objective was to
explore the impact of NTproBNP and comorbidity on the associa-
tion between overall HF or different types of HF and the risk for all-
cause and cardiovascular mortality.
2. Methods
2.1. Study population
Patients were recruited from one PHC selected from northern
Sweden between March 30, 2000 and March 11, 2003. The PHC has
a catchment area of approximately 7800 inhabitants, of whom
many are of advanced age. For many years, a computer-based
registry of all patients with a diagnosis of HF had been used by
the PHC. In 2001, this registry included 150 patients with a sus-
pected diagnosis of HF on clinical grounds. The patient population
comprised both registry patients and incident cases with suspected
HF identiﬁed by the general practitioner (GP) at the PHC during the
recruitment period. All participants had symptoms (mainly dys-
pnea) indicating chronic HF and were evaluated clinically by a GP
prior to being referred for an echocardiography (MO) and subse-
quent cardiovascular consultation. The study cardiologist (KB)
conﬁrmed or refuted the diagnosis of HF based on the GP's pre-
speciﬁed HF record, echocardiography results, and hospital records.
2.2. Diagnosis and types of HF
Global left ventricular systolic function was assessed as normal
or depressed including mildly, moderately, or severely depressed.
Normal systolic function corresponded to an ejection fraction (EF)
of 55%, and severely depressed systolic function was considered
to be an EF of <30%.
To evaluate the diastolic function (1) we used the mitral valve
inﬂow pattern as the ratio of early and atrial ﬁlling velocities of the
left ventricle; (2) the pulmonary vein ﬂow was examined in the
apical four-chamber view in the right upper pulmonary vein; and
(3) we used the isovolumic relaxation time measured in the four-
chamber view with the cursor placed between the aortic valve
and the mitral valve.
In summary, if any of the above-described diastolic variables
were abnormal, then diastolic dysfunction was established13e15
(see Table 1).
Diagnosis of HF was established according to the European
guidelines.15 Patients diagnosed with left ventricular dysfunction
alone had abnormal systolic and/or diastolic LV function, but had
symptoms considered to be caused primarily by factors other than
cardiac diseases.
We classiﬁed 170 patients (121 women and 49 men) as having
HF (systolic and/or diastolic HF) or not having HF (Fig. 1). This pa-
tient population has been described in detail previously.16
In the present longitudinal, prognostic, observational study, 144
patients from the study population were included. Patients diag-
nosed with left ventricular dysfunction were excluded (Fig. 1). Of
the 144 included patients, 77 had overall HF (systolic and/ordiastolic HF) and were compared with 67 patients with no HF
(reference group). The types of HF were deﬁned as follows: overall
HF included the three types of HFdisolated systolic HF, isolated
diastolic HF, or combined systolic/diastolic HF (combined HF).
In short, details of the patients' medical historydsuch as hy-
pertension, myocardial infarction (MI), atrial ﬁbrillation (missing,
n ¼ 30), valvular heart disease, stroke, pulmonary disease, kidney
dysfunction (creatinine > 100 mmol/L; missing, n ¼ 5), diabetes
(both types 1 and 2), smoking habits (both smoker and ex-smoker,
missing, n ¼ 10), use of alcohol (yes/no; missing, n ¼ 16), weight
(missing, n¼ 8), symptoms, and evidence-basedmedical treatment
associated with prognosisdwere collected from the GP's case re-
cord when the patients were examined at baseline.
2.3. NTproBNP
For analysis of NTproBNP, blood samples (plastic EDTA tubes)
were taken from fasting patients who had rested for 20 minutes.
After 5 minutes, the samples were centrifuged (1500e2000  g)
for 10 minutes at 4C then stored frozen at 70C. NTproBNP
was analyzed with Roche Elecsys proBNP immunoassay (Roche
Diagnostic Corporations, Indianapolis, Indiana, USA; NtproBNP
with missing information, n ¼ 11).
2.4. Outcome classiﬁcation
Death certiﬁcates were used to identify all-cause mortality, and
cardiovascular mortality was deﬁned as International Classiﬁcation
of Diseases-10 codes 100e199. The same classiﬁcationwas used for
both 3-year mortality and the 10-year follow-up (median,
4.17 years) for the 144 patients in this study.
2.5. Statistical analysis
Baseline characteristics were described as frequencies or means
and standard deviations. Differences between groups were tested
with the Student t test for normally distributed data, Man-
neWhitney U test was used for nonnormally distributed contin-
uous variables, and the Chi-square test was used for categorical
variables. The association between baseline characteristics and
mortality for 3-year was analyzed with logistic regression analysis
and at 10 years of follow-up with Cox regression analysis. In
multivariate logistic or Cox regression analyses, Model 1 included
Table 2
Characteristics at baseline, for patients dead (n ¼ 71) or alive (n ¼ 73) after 10 years
of follow-up.
Characteristic Dead Alive
n Mean (SD)
or n (%)
Mean (SD)
or n (%)
p
Age, y 144 81 ± 6.1 73 ± 8.5 <0.001
Female 102 48 (47) 54 (53) 0.401
Weight, kg 136 73 ± 14.5 76 ± 16.1 0.173
Smoker or ex-smoker 34 21 (62) 13 (38) 0.073
Hx of alcohol 27 13 (48) 14 (52) 0.973
Hx diabetes 19 12 (63) 7 (37) 0.195
Hx hypertension 64 30 (47) 34 (53) 0.602
Hx myocardial infarction (MI) 32 19 (59) 13 (41) 0.196
Hx atrial ﬁbrillation 22 15 (68) 7 (32) 0.086
Hx valvular disease 22 13 (59) 9 (41) 0.319
Hx underlying heart disease 122 63 (52) 59 (48) 0.187
Hx stroke 18 11 (61) 7 (39) 0.284
Hx pulmonary disease 16 9 (56) 7 (44) 0.556
Kidney dysfunction
(creatinine > 100 mmol/L)
38 28 (74) 10 (26) <0.001
Systolic HF 28 17 (61) 11 (39) 0.050
Diastolic HF 28 12 (43) 16 (57) 0.713
Combined systolic and
diastolic HF
21 16 (76) 5 (24) 0.003
Overall HF 77 45 (58) 32 (42) 0.019
Reference group 67 26 (39) 41 (62) 0.019
NTproBNP (ng/L) 13,321 1942 ± 3739 530 ± 1471 <0.005
ACE or ARB and BB 21 12 (57) 9 (43) 0.437
ACE ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin II receptor
blocker; BB¼ beta blocker; Hx¼ history; HF¼ heart failure; NTproBNP¼ natriuretic
peptide; SD ¼ standard deviation.
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Fig. 1. Flowchart of the study population. Patients were diagnosed with heart failure (HF) or no HF, and left ventricular dysfunction.
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variables used in Model 1 as well as other variables signiﬁcantly
(p < 0.05) associated with all-cause mortality or cardiovascular
mortality in the univariate analysis at 3 years or 10 years of follow-
up. The results are presented as the odds ratio (OR) and hazard ratio
(HR) with 95% conﬁdence interval (CI). In both multivariate logistic
and Cox regression analyses, we primarily used overall HF (cases)
together with other signiﬁcant variables from the univariate anal-
ysis. For the different types of HF diagnoses, explorative analyses
were done because of too few events.
The assumption of proportional hazard was graphically veriﬁed
using KaplaneMeier survival curves for 10-year mortality (ﬁgure
not shown). PASW statistics (SPSS Inc., Chicago), version 18.0, was
used for all statistical analyses.
Patients signed written informed consent forms for inclusion in
the study, and the study was approved by the Committee of Ethics
at Umeå University, Umeå, Sweden (diary number 00-276).
3. Results
3.1. All-cause mortality during 10 years of follow-up
Seventy-one (49%) of 144 patients died during the 10-year
follow-up period. Of those who died, 48 (68%) were women and
23 (32%) weremen. Themean agewas 81 years at baseline. Of those
who died, 25 patients (35%) died of HF, eight patients (11%) died of
cancer, eight patients (11%) died of stroke, ﬁve patients (7%) died of
lung disease, four patients (6%) died of sudden cardiac death, four
patients (6%) died of MI, and three patients (4%) died of dementia.
Overall, HF was present in 45 (63%) patients distributed into 16
(22%) patients with combined HF, 17 (24%) patients with isolated
systolic HF, and 12 (17%) patients with isolated diastolic HF
(Table 2).
Among the patients with systolic HF, 76% died from cardio-
vascular diseases, ﬁve patients (29%) died of HF, four patients
(24%) died of stroke, one patient (6%) died of sudden cardiac
death, and one patient (6%) died of MI; of the 24% fromnoncardiovascular causes, two patients (12%) died of cancer and
one patient (6%) died of lung disease. In patients with diastolic HF,
the causes of death were equally distributed (50% each) between
cardiovascular [4 patients (33%) died of HF and 2 patients (17%)
died of stroke], and noncardiovascular causes [2 patients (17%)
died of lung disease, 1 patient (8%) died of cancer, and 1 patient
(8%) died of dementia].
Table 3
Univariate and multivariate Cox regression analyses concerning the inﬂuence of HF on all-cause mortality during 10 years of follow-up.
n cases/n reference group Univariate analysis Model 1 Model 2
HR 95% CI p HR 95% CI HR 95% CI
Systolic HF 28/67 1.95 1.06e3.61 0.033 1.83 0.96e2.80 1.78 0.83e3.82
Diastolic HF 28/67 1.14 0.57e2.25 0.716
Combined HF 21/67 3.28 1.74e6.14 <0.001 2.25 1.08e4.67 1.97 0.88e4.44
Overall HF 77/67 1.86 1.15e3.01 0.012 1.64 0.96e2.80 1.39 0.78e2.47
CI ¼ conﬁdence interval; HF ¼ heart failure; HR ¼ hazard ratio; Model 1 ¼ adjustment for natriuretic peptide; Model 2 ¼ adjustment for natriuretic peptide, age, kidney
dysfunction, and smoking habits.
Table 4
Univariate Cox regression analysis for comorbidities for all-cause and cardiovascular mortality at 10 years of follow-up.
Predictor variables n cases/n
reference group
Missing n cases/n
reference group
All-cause mortality Cardiovascular mortality
HR 95% CI p HR 95% CI p
Age (per year) 77/67 0/0 1.11 1.07e1.15 <0.001 1.19 1.12e1.26 <0.001
Female 48/54 0/0 0.77 0.47e1.27 0.310 0.70 0.38e1.27 0.239
Weight (per kg) 74/62 3/5 0.99 0.97e1.00 0.128 0.98 0.96e1.00 0.070
Smoker or ex-smoker 23/11 2/8 1.88 1.12e3.17 0.017 1.82 0.94e3.51 0.073
Hx alcohol 15/12 7/9 1.04 0.56e1.92 0.902 0.71 0.30e1.69 0.435
Hx diabetes 11/8 0/0 1.62 0.87e3.01 0.131 1.40 0.60e3.31 0.439
Hx underlying heart disease 71/51 0/0 1.63 0.78e3.41 0.192 1.72 0.68e4.35 0.250
Hx hypertension 40/24 0/0 0.89 0.55e1.42 0.622 0.71 0.39e1.28 0.256
Hx myocardial infarction 23/9 0/0 1.39 0.82e2.36 0.216 1.59 0.85e2.98 0.145
Hx atrial ﬁbrillation 15/7 16/14 1.74 0.97e3.15 0.064 2.35 1.20e4.58 0.012
Hx valvular disease 13/9 0/0 1.43 0.78e2.61 0.248 1.46 0.68e3.12 0.333
Hx stroke 11/7 0/0 1.28 0.67e2.43 0.458 1.74 0.87e3.51 0.120
Hx pulmonary disease 8/8 0/0 1.34 0.66e2.70 0.413 1.18 0.47e2.99 0.724
Kidney dysfunction (Creatinine > 100 mmol/L) 25/13 3/2 2.81 1.72e4.60 <0.001 3.88 2.15e7.00 <0.001
BB and ACE or ARB 15/6 0/0 1.28 0.69e2.37 0.435 1.03 0.44e2.42 0.950
NTproBNP (per ng/L) 72/61 5/6 1.01 1.01e1.02 <0.001 1.02 1.01e1.02 <0.001
ACE ¼ angiotensin-converting enzyme inhibitors; ARB ¼ angiotensin II receptor blocker; BB ¼ beta blocker; Cases ¼ overall HF; Hx ¼ history; CI ¼ conﬁdence interval;
HR ¼ hazard ratio; NtproBNP ¼ natriuretic peptide; reference group ¼ no heart failure.
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with combined HF was 24% after 10 years. The corresponding ﬁgure
for overall HF was 42%, and was 39% for isolated systolic HF. The 10-
year survival rate for those with isolated diastolic HF was 57%.
In univariate Cox regression analysis, signiﬁcant associations
were found for overall HF, isolated systolic HF, combined HF, and
all-cause mortality, but not for isolated diastolic HF (Table 3). Age,
smoking habits, kidney dysfunction, and NTproBNP were signiﬁ-
cantly associated with all-cause mortality (Table 4).
In multivariate Cox regression, overall HF was not associated
with mortality in Model 1 or 2 (Table 3). The impact of comorbid-
ities on mortality is shown in Table 5.
Combined HF remained signiﬁcant in Model 1 (HR, 2.3; 95% CI,
1.1e4, 7), but was not signiﬁcantly associated with all-cause mor-
tality in Model 2 (HR, 2.0; 95% CI, 0.9e4.4). Systolic HF was not
signiﬁcantly associated with all-cause mortality in either Model 1
or 2 (Table 3).
If overall HF was replaced with combined HF in Model 2, age
(HR, 1.1; 95% CI, 1.03e1.17), smoking habits (HR, 4.1; 95% CI,Table 5
Results from Cox regression model for overall HF adjusted for NTproBNP, age, kidney dysf
10 years of follow-up.
Predictor variables Multivariate a
All-cause mor
HR 95% CI
Overall HF 1.32 0.74e2.36
NTproBNP (per ng/L) 1.01 1.00e1.02
Age (per year) 1.11 1.05e1.16
Kidney dysfunction (creatinine > 100 mmol/L) 1.91 1.11e3.29
Smoker or ex-smoker 3.70 2.02e6.77
History of atrial ﬁbrillation
CI ¼ conﬁdence interval; HF ¼ heart failure; HR ¼ hazard ratio; NTproBNP ¼ natriuretic1.7e9.7), and NTproBNP (HR, 1.02; 95% CI, 1.00e1.03) remained
signiﬁcantly associated with all-cause mortality.
When isolated systolic HF replaced overall HF in Model 2, age
(HR, 1.11; 95% CI, 1.04e1.18) and smoking habits (HR, 3.8; 95% CI,
1.7e8.3) remained signiﬁcantly associated with all-cause
mortality.
3.2. Cardiovascular mortality during 10 years of follow-up
Of the 71 patients who died, 47 (66%) patients (mean age,
83 years) died from cardiovascular disease. Of these patients, 31
(66%) were women and 16 (34%) were men. Overall HF was present
in 31 (66%) patients, comprising 12 (25%) with combined systolic
and diastolic HF, 13 (28%) with isolated systolic HF, and six (13%)
with isolated diastolic HF.
In univariate Cox regression analysis, there was an association
between overall HF, isolated systolic HF, combined HF, and the risk
for cardiovascular mortality, but not between isolated diastolic HF
(data not shown) and cardiovascular mortality. Age, kidneyunction on all-cause mortality but also atrial ﬁbrillation on cardiovascular mortality,
nalysis
tality
Multivariate analysis
Cardiovascular mortality
p HR 95% CI p
0.347 1.06 0.50e2.23 0.881
0.012 1.01 1.00e1.02 0.036
<0.001 1.14 1.07e1.21 <0.001
0.020 2.15 1.05e4.38 0.036
<0.001
1.58 0.71e3.51 0.264
peptide.
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associated with cardiovascular mortality (Table 4).
In multivariate Cox regression, overall HF was not associated
with mortality in Model 1 or 2. The impact of comorbidities on
mortality is shown in Table 5.
Combined HF remained signiﬁcant in Model 1 (HR, 2.8; 95% CI,
1.1e7, 0), but was not signiﬁcantly associated with cardiovascular
mortality after further adjustment in Model 2 (HR, 1.0; 95% CI,
0.3e3.3). Systolic HF was not signiﬁcantly associated with cardio-
vascular mortality in Model 1 or 2 (data not shown).
If overall HF was replaced with combined HF in Model 2, age
(HR, 1.13; 95% CI, 1.04e1.22) and NTproBNP (HR, 1.02; 95% CI,
1.00e1.03) remained signiﬁcantly associated with cardiovascular
mortality. When isolated systolic HF replaced overall HF inModel 2,
age (HR, 1.15; 95% CI, 1.07e1.24) and kidney dysfunction (HR, 2.5;
95% CI, 1.1e5.7) remained signiﬁcantly associated with cardiovas-
cular mortality.
3.3. All-cause mortality at 3 years
Twenty-ﬁve (15%) patients out of 144 had died after 3 years. Of
those who died, 16 (64%) were women and nine (36%) were men,
and their mean age was 80 years at baseline. Overall HF was found
in 19 (76%) patients, of whom eight (32%) had combined HF, ﬁve
(20%) had isolated systolic HF, and six (24%) had isolated diastolic
HF.
The 3-year mortality data demonstrated that patients with
systolic HF mainly died from cardiovascular causes compared with
noncardiovascular causes (80% vs. 20%). For patients with diastolic
HF, the proportions for cardiovascular versus noncardiovascular
mortality were 33% versus 67%.
In univariate logistic regression analysis, overall HF (OR, 3.3; 95%
CI, 1.2e8.9) and combined HF (OR, 6.3; 95% CI, 1.9e21.1) were
signiﬁcantly associated with all-cause mortality, but did not remain
signiﬁcant after adjustment for NTproBNP.
Age, smoking habits, NTproBNP, and kidney dysfunction were
signiﬁcantly associated with all-cause mortality in univariate
analysis. The only variable that remained signiﬁcant after adjust-
ment in Model 2 was smoking habits, with an OR of 8.1 (95% CI,
2.4e26.7) when overall HF was included in the model. When
overall HF was replaced with combined HF, smoking habits had an
OR of 7.1 (95% CI, 1.3e40.5).
3.4. Cardiovascular mortality at 3 years
Sixteen (57%) of 25 patients (mean age, 83 years at baseline) died
from cardiovascular disease. Of those who died, nine (56%) were
women and seven (44%)weremen.Overall HFwas found in 13 (81%)
patients, of whom seven (43%) had combined HF, four (25%) had
isolated systolic HF, and two (13%) had isolated diastolic HF.
In univariate logistic regression analysis, overall HF (OR, 4.3; 95%
CI, 1.2e15.9) and combined HF (OR: 10.7; 95%CI: 2.7e46.4) were
signiﬁcantly associated with cardiovascular mortality, but did not
remain signiﬁcant after adjustment for NTproBNP.
Age and smoking habits were signiﬁcantly associated with car-
diovascular mortality in univariate analysis and remained signiﬁ-
cant inModel 2when overall HFwas included in themodel (age: OR
1.19, 95% CI 1.01e1.39; smoking habits: OR 28.0, 95% CI 4.3e183.2).
When combined HF replaced overall HF in Model 2, only smoking
habits (OR, 47.7; 95% CI, 2.8e825.3) remained signiﬁcant.
4. Discussion
Our main ﬁnding was that overall HF, isolated systolic HF, and
combined HF, but not diastolic HF, were signiﬁcantly associatedwith all-cause and cardiovascular mortality after 10 years
of follow-up. Only combined HF remained signiﬁcant after
adjusting for NTproBNP, but not after further adjusting for age,
smoking habits, and kidney dysfunction. Another important
ﬁnding was that smoking habits was the only studied variable
that predicted all-cause mortality after both 3 years and 10 years
of follow-up.
The results after 3 years and 10 years of follow-up revealed that
the presence of systolic HFdin contrast with diastolic HFdwas a
determinant of prognosis, although not signiﬁcant after adjust-
ments. Our reference group comprised patients with symptoms
such as dyspnea and fatigue, but these were not classiﬁed as HF
symptoms because they were considered more likely to be caused
by other diseases. For women in the reference group, the survival
rate was 57% after 10 years of follow-up, which was the same as
that found for women of the same age in the Swedish population.
For males, the survival rate was 78% compared with 51% for
Swedish males.17 Thus, the men in our reference group may have
been healthier than those in the general Swedish population, but
were also younger (73 years vs. 75 years). The difference in survival
rate for males should be interpreted with caution because of the
limited number of males (n ¼ 13) in our reference group.
In contrast to our ﬁndings, a registry study in hospitalized pa-
tients with preserved systolic function, deﬁned as EF  40%, and
those with left ventricular systolic dysfunction (EF < 40%) showed
no signiﬁcant difference in unadjusted all-cause mortality after
60e90 days of follow-up after hospital discharge.18 The patients
with preserved systolic function were in parity in terms of age, and
included more females and patients with a history of hypertension
than our patients with isolated diastolic HF. By contrast, the pre-
vious study consisted of a hospitalized, prespeciﬁed subset of pa-
tients with HF, and the follow-up time was short compared with
that used in our study.
Results from a meta-analysis also pointed in the same direction
as our studydthat patients with HF and preserved left ventricular
ejection fraction (HF-PEF) had a 32% lower risk of death than pa-
tients with HF and systolic dysfunction.19 Their patients with HF-
PEF were at signiﬁcantly lower risk of death than those with HF-
REF also after adjustment for age, sex, hypertension, diabetes,
atrial ﬁbrillation, and etiology of HF. In our study, we found in the
univariate logistic regression analysis at 3 years, an HR of 0.80 for
patients with isolated diastolic HF when compared to patients with
isolated systolic HF, although it is not signiﬁcant, probably because
of the limited number of patients. The above meta-analysis
(n ¼ 50,991 patients) included both observational studies and
randomized trials with 3 years of follow-up but their patients were
younger and with fewer women than in our study.
The Olmsted community study of patients with preserved EF
(50%) and reduced EF (50%) from a random sample of all po-
tential HF cases, including both hospitalized individuals and out-
patients, showed different results compared with ours.20 There
weremoremales and fewer patients with a history of hypertension,
and the mortality rate was 86% compared with 49% in our study
with the same follow-up time. Noncardiovascular causes accounted
for 49% of deaths in their patients with preserved EF, which was
similar to our results (50%). By contrast, noncardiovascular causes
accounted for 36% of deaths in their patients with reduced EF
compared with 24% in our patients with systolic HF. This may
suggest that patients in the Olmsted community study20 with
reduced EF had more severe illness than our patients.
Obviously, our patients with systolic HF died more often from
cardiovascular than noncardiovascular causes than did patients
with diastolic HF. Thismay be because cardiovascular comorbidities
increase with time, and/or an increasing death rate among patients
with systolic HF.
Fig. 2. KaplaneMeir plots showing proportions of patients who were alive during
10 years of follow-up for 77 patients with overall heart failure (HF) and 67 patients
with no HF at baseline.
M. Olofsson, K. Boman / Journal of Clinical Gerontology & Geriatrics 6 (2015) 20e26 25NTproBNP is a well-known prognostic factor, but has mostly
been studied in younger patients. Only combined HF together with
NTproBNP remained signiﬁcantly associated with a risk of mor-
tality after 10 years of follow-up. This strengthens the notion that
NTproBNP is a strong prognostic factor even in elderly patients with
HF.
After 3 years and 10 years of follow-up, smoking habits had a
greater impact on all-cause mortality than a diagnosis of HF. After
10 years of follow-up, kidney dysfunction, NTproBNP, and age were
also signiﬁcantly associated with all-cause mortality.
The Olmsted study20 found that advanced age, male sex, dia-
betes, smoking, and kidney disease were associated with an
increased risk of mortality. Our results are in line with the results of
that study except for the sex differences. Diabetes seemed to be an
important comorbidity factor in our study at 3 years in univariate
analysis of all-cause mortality with borderline signiﬁcance
(p ¼ 0.090). The ﬁndings for diabetes mellitus (DM) merit further
investigations in these elderly patients. There are a number of
potential prognostic factors that may affect prognosis in patients
with DM. These include associated atherosclerotic complications,
hypoglycemia episodes, and drug interaction.21,22
4.1. Methodological considerations
Our study was planned and performed in the late 1990s and
performed during the ﬁrst years of 2000. During that time, HF with
preserved ejection (HF-PEF) was not used as a diagnostic criterion
but diastolic HF was the main deﬁnition although not uniformly
agreed upon. We have used the proposal made by the European
Society of Cardiology guidelines 2001. For the diagnosis of CHF, the
response to treatment was also included. HF-PEF is still difﬁcult to
deﬁne, and there is no consensus on the optimal cutoff value for EF.
It is also important to emphasize that a normal EF is not equivalent
to a normal systolic function. In our study, we had three cases with
EF 55% although they were categorized as having systolic HF. One
case had aortic stenosis with left ventricular hypertrophy. The two
others had severe mitral incompetence with large afterload re-
ductions. These three cases responded very well to drug and sur-
gical treatment, which explains why they were classiﬁed as systolic
HF according to earlier guidelines.
4.2. Clinical implications
Our study provides further knowledge on elderly patients with
HF who are managed mainly in the PHC setting, with follow-up for
10 years: ﬁrst, the prognostic importance of systolic HF rather than
diastolic HF in these patients should be considered; second, the
importance and often overlooked impact of comorbidities, espe-
cially renal dysfunction but also diabetes, should be considered.
Third, the impact of smoking/having smoked should not be
forgotten, even in elderly patients. Taken together for the GP in
clinical practice who wants to predict 10-year outcome, systolic HF,
NTproBNP, renal dysfunction, and smoking habits are the main
predictors of mortality. If the GP has a patient with isolated systolic
HF or kidney dysfunction, the prognosis is poor in 10 years for both
all-cause and cardiovascular mortality, and the need for NTproBNP
is not obviously necessary unless there is a requirement for more
precise prognostic information. By contrast, according to this study,
if an elderly patient has a high NTproBNP value, the 10-year
prognosis is poor for both all-cause and cardiovascular mortality.
4.3. Limitations
The study population is limited. Data for clinical variables were
collected from the GP's prespeciﬁed HF record, but were notvalidated. Some data for clinical variables were missing for un-
known reasons. For clinical diseases, missing data were regarded as
absence of disease. Validationwas done for HF, but not for any other
clinical diseases. The Cox analyses for diastolic HF should be
interpretedwith caution because of some violations of the curves in
the KaplaneMeier plot (Fig. 2).
4.4. Strengths
The major strengths of this study are the long-term, 10-year
follow-up, and inclusion of protocol-based patients from one PHC,
and that HF was veriﬁed by echocardiography in all patients. The
reference group consisted of patients with symptoms suggestive of
HF, but who were not considered to have HF. This resembles daily
clinical practice when the GP encounters a patient with breath-
lessness and fatigue.
5. Conclusion
In this long-term follow-up study, a patient with a diagnosis of
systolic HF had a worse prognosis for mortality than a patient with
diastolic HF when compared with the reference group. Age is not
modiﬁable, but recognizing and counseling patients on smoking
habits remains of great importance in elderly patients seen in the
PHC setting. Attention to comorbidities such as kidney dysfunction
and DM should also be emphasized.
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